Cargando…
PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
INTRODUCTION: Randomised clinical studies in psoriatic arthritis (PsA) do not always reflect patients in routine clinical practice. Large-scale data from routine practice are needed to better understand drug persistence, effectiveness and long-term safety of therapeutic agents. METHODS: PsABIOnd is...
Autores principales: | Siebert, Stefan, Behrens, Frank, Lubrano, Ennio, Martin, Nicolas, Sharaf, Mohamed, Contré, Christine, Theander, Elke, Queiro, Rubén, Zimmermann, Miriam, Gossec, Laure |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011238/ https://www.ncbi.nlm.nih.gov/pubmed/36585602 http://dx.doi.org/10.1007/s40744-022-00518-w |
Ejemplares similares
-
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023) -
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022) -
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022) -
Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021) -
Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)